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Edited by Hans-Dieter KlenkAbstract Hepatitis C virus non-structural protein NS5A plays
an important role in viral replication and various cellular events.
To gain further insight into the function of NS5A, we screened a
human fetal liver cDNA library for its interacting proteins using
the yeast two-hybrid system. FKBP38, a 38 kDa immunosup-
pressant FK506-binding protein, was identiﬁed and its interac-
tion with NS5A was conﬁrmed by both in vitro and in vivo.
The interaction was mapped to the amino acids 148–236 of
NS5A containing a BH domain (Bcl-2 homology domain). Be-
sides, both NS5A and FKBP38 were found to localize in mito-
chondria and endoplasmic reticulum. Moreover, NS5A stably
expressing Huh7 hepatoma cells showed more resistance to
apoptosis and such inhibition of apoptosis could speciﬁcally be
abrogated by depletion of FKBP38 using RNA interference.
These results indicate that HCV NS5A inhibits apoptosis
through interaction with FKBP38.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hepatitis C virus (HCV) is a major causative agent for acute
and chronic hepatitis, which may often progress to liver cirrho-
sis and hepatocellular carcinoma (HCC) [1,2]. It is estimated to
infect up to 200 million persons worldwide, corresponding to
more than 3% of the world population [3]. The current ther-
apy, pegylated interferon, alone or in combination with ribavi-
rin, is still not eﬀective enough especially in patients infected
with genotype 1b [4,5]. HCV study was hampered by the lack
of an eﬃcient tissue culture system or an adequate small ani-
mal model of HCV infection, although the establishment of
HCV subgenomic replicons and very recently, the HCV
JFH-1 replicons enabling secretion of infectious viral particlesAbbreviations: HCV, hepatitis C virus; NS, non-structural protein;
FKBP38, 38kDa FK506-binding protein; HCC, hepatocellular carci-
noma; GFP, green ﬂuorescent protein; HA, inﬂuenza hemagglutinin;
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doi:10.1016/j.febslet.2006.07.002has been a great breakthrough in HCV research [6,7]. At
present, the mechanism of HCV replication, persistence and
pathogenesis is still unclear.
HCV is a member of the positive strand RNA viruses
belonging to the family Flaviviridae and contains a genome
of approximately 9.5 kb in length, which encodes a large poly-
protein precursor of about 3000 amino acids. This precursor
polypeptide is then cleaved by both host and viral proteases
to produce structural (core, E1, E2, and P7) and non-struc-
tural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) proteins
[8,9]. Among all of the viral proteins, NS5A has been demon-
strated to play an important role in viral replication by coor-
dination with cellular and other non-structural proteins to
form a membranous web in infected cells [10]. In addition to
its role in viral replication, a number of studies have shown
that NS5A is a multi-functional protein involved in many cel-
lular events, many of which would ultimately result in viral
persistence and pathogenesis. For example, NS5A expression
could alter intracellular calcium and reactive oxygen species
levels and in turn activate STAT-3 and NF-jB [11,12].
NS5A could inhibit the activity of the mitogenic and stress
activated transcription factor activating protein-1 (AP1) by
interfering with Ras-ERK pathway [13]. Cell cycle studies
using NS5A expressing cell lines suggested the expression of
NS5A may lead to a reduced S phase and an increase in the
G2/M phase [14].
Recently, many studies have focused the anti-apoptosis
function on single HCV protein since a growing body of evi-
dence has shown interference with apoptosis could prolong
the life of infected cells, resulting in enhanced viral replication
and a contribution to viral persistence and pathogenesis.
Therefore, after infection, the virus has developed distinct
strategies to escape or retard apoptosis triggered by the various
apoptotic pathways. For example, the NS2 protein of HCV
could interact with a liver-speciﬁc pro-apoptotic protein
CIDE-B and inhibit CIDE-B induced apoptosis [15]. HCV
core protein could suppress apoptosis through upregulation
of inhibitor of caspase-activated DNase [16]. Among all of
the viral proteins, NS5A has been demonstrated to employ
multiple strategies to perturb apoptosis. For instance, NS5A
could interact with pro-apoptotic molecule Bin1 and Bax, per-
turb the mitogenic signaling pathway, and protect cells against
TNF-a- and p53-mediated apoptosis [17–22]. However, there
is still lacking of the overall understanding of the molecular
mechanism of NS5A in mediating cell apoptosis.
To gain further insight into the function of NS5A, we car-
ried out yeast two-hybrid analysis using a NS5A isolate withblished by Elsevier B.V. All rights reserved.
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human fetal hepatocyte cDNA library. In this work, we iden-
tiﬁed a 38 kDa immunosuppressant FK506-binding protein
38 kDa FK506-binding protein (FKBP38) as a new NS5A
interacting protein. FKBP38 was previously reported to inter-
act with anti-apoptotic molecule Bcl-2, target Bcl-2 into the
mitochondria and inhibit apoptosis [23]. The interaction be-
tween NS5A and FKBP38 was conﬁrmed by coimmunoprecip-
itation and confocal microscopic assays in vitro and in vivo.
Further study showed the segment of NS5A containing BH1
domain was essential for association with FKBP38. Immuno-
ﬂuorescence staining showed both NS5A and FKBP38 were
found to reside in mitochondria and endoplasmic reticulum.
To further explore the role of NS5A in cell apoptosis, NS5A
stably expressing Huh7 hepatoma cells was constructed in
which Bcl-2 expression was deﬁcient. Apoptosis assay showed
that, compared to control cells, it was more resistant to apop-
tosis. More importantly, such resistance to apoptosis could be
speciﬁcally abrogated by suppression of endogenous FKBP38
using RNA interference. These results uncover a novel interac-
tion between NS5A and FKBP38 conferring the anti-apoptotic
function to NS5A.2. Materials and methods
2.1. Construction of NS5A
The cloning of full-length NS5A from HCV genotype 1b patient was
done as described [24] and the full-length NS5A was used as template
for construction of NS5A truncated mutants by PCR ampliﬁcation
with appropriate sequence speciﬁc primers and ExTaq polymerase
(Takara).
2.2. Yeast two-hybrid assays
The Yeast AH109 reporter strain transformed with plasmid
pGBKT7 containing the full-length NS5A was used to screen the hu-
man fetal liver MATCHMAKERGal4 cDNA library (Clontech) using
the reporter genes HIS, ADE and MEL. The cDNA library was
screened as described in the manufacturer’s protocol (Clontech). The
positive clones that contained cDNA encoding putative NS5A-inter-
acting proteins were sequenced and subjected to BLAST analysis.
For mapping the interacting domain of NS5A, a series of truncated
mutants of NS5A and full-length FKBP38 were cotransformed into
AH109 yeast strains respectively and selected on Leu/Trp/His/Ade
deﬁcient plates.
2.3. In vitro binding assay
The full-length cDNA of FKBP38 was cloned into pcDNA3/HA
vector. The plasmids pGBKT7-NS5A and pcDNA3/HA-FKBP38 were
used as templates in protein translation using the TNT quick coupled
transcription/translation system (Promega). [35S] Methionine (Amer-
sham)-labeled NS5A and HA-FKBP38 were incubated with monoclo-
nal anti-HA antibody (Babco) in lysis buﬀer (50 mM Tris–HCl [pH
7.5], 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, 1 mM phenylmethyl-
sulfonyl ﬂuoride), followed by adsorption to BSA blocked protein A/G
plus-agarose (Santa Cruz). The beads were washed thrice with lysis
buﬀer (50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA,
0.1% NP-40). The antibody–protein complexes were then resolved in
12% SDS–PAGE and subjected to autoradiography.
2.4. Cell culture
Cos7 cells (African Green Monkey kidney cells) and human hepa-
toma cell line Huh7 cells were propagated in DMEM supplemented
with 10% FCS, 2 mM L-glutamine, 100 IU/ml penicillin and 100 lg/
ml streptomycin. The BB7 HCV subgenomic replicons (genotype 1b)
were obtained from Dr. Charles M. Rice (The Rockefeller University,
New York). Huh-7 cells were transfected with HCV subgenomic repli-
con RNA and maintained as described [25]. Huh-7 clone R cells har-boring autonomously replicating HCV replicon RNA were used in
related experiments. For NS5A stably expressing cell line, Huh7 cells
were transfected with pcDNA3.1/myc-His-NS5A or empty vectors
using Fugene6 (Roche). Sixteen hours post transfection, medium was
changed and supplemented with 0.5 g/l of neomycin (Gibco/BRL).
After culturing in selection medium for three weeks, the individual
neomycin-resistant clones were isolated. One clone expressing the neo-
mycin resistance gene (vector) and two clones expressing NS5A (5AC1
and 5AC2) were selected for the further study.
2.5. Immunoprecipitation and immunoblotting analysis
To establish a system for validating the interaction in mammalian
cells, Cos7 cells were cotransfected with pcDNA3/HA-FKBP38 and
pcDNA3.1/myc-His-NS5A or their empty plasmids, or HCV subge-
nomic replicons were transfected with pcDNA3/HA-FKBP38 or
pCMV/HA-FKBP51(Kindly gift from Dr. David F. Smith, Johnson
Research Center, Mayo Clinic Scottsdale), respectively. Forty-eight
hours post transfection, cells were lysed in 1 ml of lysis buﬀer
(50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1% NP-40, 5 mM
EDTA, 5 mM EGTA, 15 mM MgCl2, 60 mM b-glycerol phosphate,
0.1 mM sodium orthoranadate, 0.1 mM NaF, 0.1 mM benzamide,
10 lg/ml aprotinin, 10 lg/ml leupeptin, 1 mM PMSF). For endoge-
nous immunoprecipitation, 1 · 107 HCV subgenomic replicons were
lysed directly. The lysates were pre-cleaned with protein A/G plus-
agarose by rotating at 4 C for 2 h. The indicated antibody was
then added into the supernatant in the presence of 40 ll fresh pro-
tein A/G plus-agarose and incubated at 4 C overnight. The immu-
noprecipitates were separated by SDS–PAGE, followed by
immunoblotting analysis using appropriate antibody. For immuno-
blotting analysis, equal quantity of cell lysates was separated by
10% SDS–PAGE. The proteins were electroblotted onto the nitro-
cellulose membrane (Roche) and incubated with the indicated
primary antibody, after incubated with the horseradish peroxi-
dase-conjugated secondary antibody (Santa Cruz), the antibody–
antigen complexes were visualized using chemiluminescence reagent
(Perkin–Elmer).
2.6. Immunoﬂuorescence staining and confocal microscopic assay
Cos7 cells seeded in a six-well chamber with coverslips were cotrans-
fected with plasmids pcDNA3/HA-FKBP38 and either pEGFPC2-
NS5A or pEGFPC2 by calcium–phosphate method. Forty-eight hours
post transfection, cells were ﬁxed with 2% formaldehyde and perme-
abilized with 0.2% Triton X-100 in PBS containing 1% fetal calf ser-
um. Samples were then incubated with mouse anti-HA monoclonal
antibody at 4 C overnight. After being washed thrice with PBS con-
taining 1% fetal calf serum, samples were incubated at 37 C for 1 h
with a rhodamine-conjugated anti-mouse secondary antibody. After
further wash, coverslips were ﬁnally mounted on glass plates and cells
were observed using confocal laser scanning microscope (Leica, TCS-
SP2). For staining of endogenous FKBP38 and NS5A, HCV
subgenomic replicons were ﬁxed, permeated and incubated with
anti-NS5A and anti-FKBP38N1 antibodies (kindly gift of Michiko
Shirane). After incubated with corresponding secondary FITC- or
Rhodamine-conjugated antibodies, cells were visualized with confocal
laser scanning microscope. For mitochondrial staining, HCV subge-
nomic replicons were stained with 50 nM Mito Tracker Orange
CMTRos (Molecular Probes) for 45 min at 37 C and then ﬁxed and
incubated with anti-NS5A or anti-FKBP38 antibody. For endoplas-
mic reticulum colocalization, HCV subgenomic replicons were ﬁxed
and stained with anti-FKBP38 antibody and either endoplasmic
reticulum speciﬁc protein disulﬁde isomerase (PDI) antibody or
anti-b-actin antibody, or HCV subgenomic replicons were transfected
with pEGFPC2-NS5A and stained with either anti-PDI or anti-b-actin
antibody and immunoﬂuorescent staining was carried out as described
above.
2.7. Subcellular fractionation analysis
The subcellular fractionation analysis was carried out as described
[23]. Brieﬂy, HCV subgenomic replicons were washed with PBS, resus-
pended in CFS buﬀer (10 mM HEPES–NaOH (pH 7.2), 0.22 M man-
nitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM KH2PO4, 0.5 mM EGTA,
2 mM MgCl2, 5 mM sodium pyruvate, 0.1 mM PMSF and 1 mM
dithiothreitol) and homogenized by aspiration through a 22-gauge nee-
dle. The homogenate was centrifuged at 750 · g for 5 min, and the
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10000 · g to obtain a pellet highly enriched in mitochondria and a
postmitochondrial supernatant as the cytosolic fraction.
2.8. Induction and detection of apoptosis
For induction of apoptosis, NS5A stably expressing Huh7 cell lines
and control cell line were deprived of serum for 4 h and then exposed
to staurosporine (1 lM; 8 h, Sigma) or cycloheximide (100 lg ml1;
24 h, Sigma). Apoptosis was evaluated by FACScan ﬂow cytometer
using Cell Quest software. The percentage of apoptosis was quanti-
tated from sub-G1 events and data were presented as the means + S.D.
Morphological changes in the nuclear chromatin in cells undergoing
apoptosis were detected by staining with the DNA binding ﬂuoro-
chrome DAPI. Cells growing on coverslips were transfected with siR-
NA and then treated with staurosporine. After being washed twice
with PBS and ﬁxed by incubation in 2% formaldehyde for 30 min, cells
were incubated with DAPI for 5 min and observed by ﬂuorescence
microscope. To detect the 85 kDa cleaved PARP product of the cells
undergoing apoptosis, 40 lg of total proteins were extracted and sub-
jected to immunoblotting analysis using anti-PARP antibody (Sigma).
The content of b-actin was used as internal control.
2.9. Depletion of FKBP38 by RNA interference
One scramble siRNA as a negative control and four candidate siR-
NA duplexes targeting the ORF of FKBP38 were obtained from
Shanghai GENECHEM Co., Ltd: siRNA1: 5 0-AAGAGUGGCUG-
GACAUUCUGG-3 0, siRNA2: 5 0-GCCAAAGTGGACATGACGT-Fig. 1. NS5A associates with FKBP38. (A) In vitro binding assay between
translated in vitro with [35S] methionine incorporation. After translation NS
HA antibody, the antibody–protein complex was resolved in 12% SDS–PAG
in vivo. Cos7 cells were co-transfected with the expression vectors pcDNA
empty plasmids. Cell lysates were immunoprecipitated with anti-myc antibody
antibody. The expression of HA-FKBP38 and NS5A-myc were conﬁrmed by
HCV subgenomic replicon lysates were incubated with anti-FKBP38 antibod
immunoblotting using anti-NS5A antibody, the asterisk shows the band
subgenomic replicons were transfected with pCMV/HA-FKBP51 or pcDN
cipitation analysis was done as described above.3 0, siRNA3: 5 0-CAGACAACATCAAGGCTCT-30, siRNA4: 5 0-CT-
GGAACCTTCCAACAAGA-3 0. 200 nM siRNA were transfected into
one well of a 24-well plate using oligotransfectamine (Invitrogen) with
no more than 50% of the cell conﬂuence. Forty-eight hours post trans-
fection, cells were harvested and the content of FKBP38 was assayed
by immunoblotting. The eﬃciency of inhibition was conﬁrmed by three
independent experiments.3. Results
3.1. HCV NS5A physically associates with FKBP38 in vitro
To identify the cellular proteins interacting with NS5A,
full-length NS5A with genotype 1b from an IFN treatment-
resistant patient was used to screen a human fetal liver cDNA
library. After second round screening, several clones encoded a
38 kDa immunosuppressant FK506-binding protein FKBP38.
To verify the result from yeast two-hybrid screening, full-length
NS5A and tagged protein HA-FKBP38 were translated in vitro
in the presence of [35S] methionine (Fig. 1A, lanes 1 and 2) and
in vitro binding assay was then performed. As shown in
Fig. 1A, NS5A could be pulled down with HA-FKBP38 in
the presence of anti-HA antibody (Fig. 1A, lane 3), while no
protein could be detected in the absence of HA-FKBP38NS5A and FKBP38. NS5A and Tagged protein HA-FKBP38 were
5A and HA-FKBP38 were immunoprecipitated with monoclonal anti-
E and subjected to autoradiography. (B) NS5A interacts with FKBP38
3/HA-FKBP38 and pcDNA3.1/myc-His-NS5A, or the corresponding
, immunoprecipitates were analyzed by immunoblotting using anti-HA
immunoblotting using anti-HA or anti-myc antibody, respectively. (C)
y or rabbit normal IgG, the immunocomplexes were then analyzed by
of NS5A immunoprecipitated by anti-FKBP38 antibody. (D) HCV
A3/HA-FKBP38 with or without 1uM FK506, and the immunopre-
Fig. 2. Confocal microscopic analysis for the association between NS5A and FKBP38. (A and B) Cos7 cells seeded on coverslips were co-transfected
with expression vectors encoding HA-FKBP38 with either GFP-NS5A (A) or GFP (control, B). Forty-eight hours post transfection, cells were ﬁxed
and immunostained with anti-HA antibody and rhodamine-conjugated secondary antibody, then observed under confocal laser scanning
microscope. Images recorded in green (GFP) and red (rhodamine) channels are presented on the left and middle, respectively, and composite images
are shown in the right. (C) HCV subgenomic replicons were ﬁxed and immunostained with anti-NS5A and anti-FKBP38 antibodies and
corresponding FITC or rhodamine-conjugated secondary antibodies, then cells were observed as described above.
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FKBP38 in vitro.
3.2. Interaction of HCV NS5A and FKBP38 in mammalian cells
We then carried out coimmunoprecipitation assay to con-
ﬁrm their association in mammalian cells. Cos7 cells were
cotransfected with pcDNA3/HA-FKBP38 and pcDNA3.1/Fig. 3. Mapping of NS5A regions responsible for the association with FKB
domains (Bcl-2 homology domain) within NS5A are indicated. The corres
transformation assays were performed with truncated mutants of NS5A and
positive (+) or negative () based on cell growth and a-galactosidase assay.myc-His-NS5A plasmids or corresponding empty plasmids.
Cell lysates were immunoprecipitated (IP) with anti-myc
antibody, and then analyzed by immunoblotting (IB) using
anti-HA antibody. As shown in Fig. 1B, HA-FKBP38 could
directly associate with NS5A-myc only when both proteins
were expressed. To further conﬁrm this result, cell lysates were
immunoprecipitated with reciprocal antibodies and same resultP38. Schematic representation of the full-length NS5A and three BH
ponding truncated mutants of NS5A were constructed and yeast co-
full-length FKBP38 plasmid, respectively. The interactions were scored
Fig. 4. Colocalization of NS5A and FKBP38 in mitochondria and endoplasmic reticulum. HCV subgenomic replicons were stained with
mitochondria speciﬁc dye Mito Tracker (red) and incubated with anti-FKBP38 or anti-NS5A antibody and corresponding FITC-conjugated
secondary antibodies (green), cells were observed using confocal laser scanning microscope. For endoplasmic reticulum staining, HCV subgenomic
replicons were ﬁxed and stained with anti-FKBP38 antibody and either endoplasmic reticulum speciﬁc protein disulﬁde isomerase (PDI) antibody or
anti-b-actin antibody, or HCV subgenomic replicons were transfected with pEGFPC2-NS5A and then ﬁxed and stained with anti-PDI or anti-b-actin
antibody, cells were observed as described above.
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binding in the context of HCV replication, HCV subgenomic
replicons harboring autonomously replicating HCV RNA
were used. Cell lysates were immunoprecipitated with anti-
FKBP38 or rabbit normal IgG and immunoblotting assay
was then performed using NS5A antibody to detect NS5A pro-
tein in the immunocomplex. As shown in Fig. 1C, NS5A could
directly associate with endogenous FKBP38 in HCV subge-
nomic replicons. Since FKBP38 was a member of FKBP sub-
family and acted as an immunosuppressant FK506-binding
protein, to detect the speciﬁcity of the interaction between
NS5A and FKBP38, HCV subgenomic replicons were trans-
fected with pCMV/HA-FKBP51 or pcDNA3/HA-FKBP38
with or without FK506. Results showed that, there was no
interaction between NS5A and FKBP51 and the association
between NS5A and FKBP38 was not aﬀected in the presence
of FK506, indicating such interaction was FK506-independent
(Fig. 1D). The above results suggested NS5A could speciﬁcally
interact with FKBP38 in vivo.Fig. 5. Anti-apoptotic action of NS5A in Huh7 hepatoma cells. (A)
Expression of Bcl-2 in Hela, Huh7 and HCV subgenomic replicons. (B)
Characterization of NS5A stably expressing Huh7 cells. Two NS5A
stable cell lines (5AC1 and 5AC2) and control cell line (Vector) were
lysed and expression of NS5A and FKBP38 was detected by
immunoblotting, the content of b-actin as internal control. (C)
NS5A stably expressing Huh7 cell lines and its control cell line were
deprived of serum for 4 h and then stimulated with staurosporine
(1 lM) or cycloheximide (100 lg/ml), respectively. The percentage of
apoptotic cells was determined with ﬂow cytometer.3.3. Colocalization of HCV NS5A and FKBP38 in mammalian
cells
To elucidate whether there was a colocalization between
NS5A and FKBP38, Cos7 cells were transiently cotransfected
with plasmids pcDNA3/HA-FKBP38 and either pEGFPC2-
NS5A or pEGFPC2. Cells were assayed by immunoﬂuores-
cence staining and visualized with confocal laser scanning
microscope. As shown in Fig. 2A, GFP-NS5A could com-
pletely colocalize with HA-FKBP38 in the cytoplasm
(Fig. 2A, right). As a negative control, GFP protein was found
to distribute in both cytoplasm and nucleus and no overlap
could be detected (Fig. 2B). Further veriﬁcation in HCV sub-
genomic replicons was done to detect their localization in the
context of viral replication. Both NS5A and endogenous
FKBP38 were found to localize in cytoplasm (Fig. 2C, left
and middle) and merged together (Fig. 2C, right).
3.4. Mapping the interacting domain within NS5A
To map the precise NS5A domain responsible for binding
FKBP38, a series of truncated mutants of NS5A were con-
structed and their binding activities were determined using
yeast two-hybrid analysis. As shown in Fig. 3, FKBP38 inter-
acted with the C-terminal deletion mutant of NS5A (aa 1–236),
while another NS5A mutant (aa 1–147) could not, implying
the NS5A segment aa 148–236 maybe important in mediating
the interaction with FKBP38. It was reported that NS5A con-
tained three Bcl-2 homology domains (BH domain) that were
crucial in inhibiting apoptosis (Fig. 3, upper) [20]. Our results
suggested that the amino acid residues 148–236 of NS5A con-
taining a BH1 domain may play an important role in mediat-
ing the interaction with FKBP38.
3.5. Mitochondrial and endoplasmic reticulum localization of
NS5A and FKBP38
Since FKBP38 was previously reported to localize in mito-
chondria while NS5A was mainly in the endoplasmic reticulum
(ER), then the subcellular localization of NS5A and FKBP38
was investigated in HCV subgenomic replicons by comparing
the immunostaining of mitochondria, ER speciﬁc protein
disulﬁde isomerase (PDI) and b-actin ﬁlaments (Fig. 4A).
FKBP38 was shown to be colocalized with both mitochondriaand ER speciﬁc marker protein PDI of the cells, but not with
the b-actin, indicating ER was also a subcellular compartment
for FKBP38. More importantly, NS5A was also found to be
colocalized with mitochondria. However, since the antibodies
for NS5A, PDI and b-actin were all monoclonal antibodies,
to perform the double-immunoﬂuorescence staining, the
HCV subgenomic replicons were transfected with pEGFPC2-
NS5A to detect its colocalization with PDI or b-actin. As ex-
pected, GFP-NS5A could colocalize with PDI.
To conﬁrm the mitochondrial targeting of NS5A and
FKBP38, we carried out subcellular fractionation analysis
using HCV subgenomic replicons. Consistent with our immu-
noﬂuorescence data, both NS5A and endogenous FKBP38
were mainly retained in the mitochondrial fraction containing
the mitochondrial protein heat shock protein 60 (HSP60), and
little was detected in the cytosolic fraction containing IjBa
(Fig. 4B).
3.6. Expression of NS5A in Huh7 hepatoma cells inhibits
apoptosis
Since NS5A contained three BH domains and localized in
mitochondria while FKBP38 was reported to target Bcl-2 into
mitochondria and inhibit apoptosis, to assess the capability of
NS5A in regulating apoptosis and exclude the impacts of Bcl-
2, we constructed NS5A stably expressing Huh7 hepatoma
cells in which Bcl-2 expression was deﬁcient (Fig. 5A). We then
chose two NS5A stable cell lines (5AC1 and 5AC2) and one
control cell line (Vector) for further investigation (Fig. 5B).
Cells were induced with pro-apoptotic drugs staurosporine
and cycloheximide, respectively. In our experimental condi-
tions, NS5A stable cells showed more resistance to apoptosis
compared to vector cells and cells were more sensitive to
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showed the function of NS5A in inhibiting apoptosis.
3.7. The anti-apoptosis function of NS5A is through the
interaction with FKBP38
In order to investigate whether such anti-apoptotic property
of NS5A was through the interaction with FKBP38, RNA
interference was carried out to inhibit the expression of endog-
enous FKBP38. As seen in Fig. 6A, two RNAi sequences (siR-
NA3 and siRNA4) could signiﬁcantly suppress FKBP38
expression. We then chose one NS5A stable cell line (5AC2)
and one RNAi sequence (siRNA3) for the next experiments.
After cells were transfected with siFKBP38 and treated with
staurosporine, there were an increasing number of apoptotic
cells in NS5A stable cells compared to the cells treated with
control siRNA. More importantly, almost no diﬀerences could
be detected in vector cells treated with siFKBP38 or control
siRNA (Fig. 6B). DAPI staining also showed that more con-
densed or fragmented nuclei could be observed in NS5A stable
cells treated with siFKBP38 (Fig. 6C). To further conﬁrm the
above results, we also detected the cleavage of PARP products
which could be cleaved by activated Caspase-3 after cells
undergoing apoptosis. Results showed that more cleaved
PARP products (85 kDa) could be detected after treatmentFig. 6. Inhibition of FKBP38 speciﬁcally restores apoptosis in NS5A stably
FKBP38 was suppressed by RNA interference. Cells were transfected with
targeting FKBP38. The content of FKBP38 was determined by immunoblot
The inhibition eﬃciency was determined by three independent experiments
transfected with scramble siRNA or siFKBP38 for 48 h, cells were incubate
counted using FACS by propidium iodide staining (upper), the inhibitory
internal control (lower). (C and D) Cells described above were also stained wi
immunoblotted to determine the cleavage products of PARP (D).of siFKBP38 in NS5A stable cells, while no diﬀerences could
be seen in vector cells (Fig. 6D). Taken together, these results
suggested NS5A could speciﬁcally inhibit apoptosis by interac-
tion with FKBP38.4. Discussion
HCV infection often leads to chronic hepatitis, liver cirrhosis
and HCC. The mechanism for HCV persistent infection is still
unclear. Among diﬀerent antiviral defense systems developed
by the cell, the programmed cell death, or apoptosis, signiﬁ-
cantly contributes to clear the virus infected cells. To survive,
viruses elaborate multiple protective strategies to interfere
apoptosis at diﬀerent levels. The anti-apoptotic property of
NS5A has been widely investigated. NS5A can protect against
the tumor necrosis factor alpha-mediated apoptotic cell death
[17,18], interact with Bin1 and inhibit apoptosis [22]. It can
also directly interact with p53 and inhibit p53-mediated apop-
tosis by sequestering p53 in cytoplasm [19]. NS5A was also
demonstrated to form a complex with phosphatidylinositol
3-kinase in EGF signaling pathway, enhance the PI3K-AKT
pathway and contribute to cell survival in virus-infected cells
[21]. Recently, it was also reported that NS5A contained threeexpressing Huh7 hepatoma cells. (A) The expression of endogenous
water (Mock), scramble control siRNA or four candidate siRNAs
ting. The expression of b-actin was determined as an internal control.
. (B) After NS5A stably expressing Huh7 cells and vector cells were
d with staurosporine for 8 h and the percentage of apoptotic cells was
eﬃciency of FKBP38 was determined by immunoblotting, b-actin as
th DAPI to observe the condensation of nucleus (C) or cell lysates were
J. Wang et al. / FEBS Letters 580 (2006) 4392–4400 4399BH domains and the BH2 domain of NS5A were required to
bind Bax and inhibit apoptosis by sequestering it in the nucleus
[20]. Although these evidences give some clues for the role of
NS5A in mediating apoptosis, the overall anti-apoptosis mech-
anism developed by NS5A is still unknown. It is presumed that
diﬀerent pathways are involved.
FKBP38 belongs to a family of immunosuppressant FK506-
binding proteins (FKBPs), which is a subfamily of a super fam-
ily of peptidylprolyl cis/trans isomerases (PPIase). PPIase is
known to be involved in many cellular processes such as cell sig-
naling, protein traﬃcking and transcription [28,29]. So far little
has been known about its function in HCV infection until very
recently another subfamily member cyclophilin B has been
shown to interact with NS5B and regulate viral replication
[30]. To date, seven mammalian FKBPs have been found in hu-
man. However, little has been known about their role in medi-
ating apoptosis except FKBP38. In our work, we also tested the
interaction between NS5A and other FKBP member such as
FKBP51. However, no interaction was found, suggesting the
association between FKBP38 and NS5A maybe speciﬁc.
It is interesting that NS5A also contains three Bcl-2 homol-
ogies, whereas FKBP38 has been demonstrated to associate
with Bcl-2 and exert its anti-apoptosis function by targeting
Bcl-2 on the outer-membrane of mitochondria. The NS5A
interacting domain was also located on the region of aa 148–
236 containing a BH1 domain. There have been a great num-
ber of evidences showing that many viruses such as herpesvirus
saimiri (HVS), Epstein Barr virus, etc. have been found to em-
ploy BH domains to evade apoptosis during infection. By
using BH domains these viral proteins could interact with
pro-apoptotic Bcl-2 members such as Bax to inhibit apoptosis
[26,27]. Our results imply HCV may also adopt similar strategy
to evade apoptosis and establish persistent viral infection.
In addition to BH domains within NS5A, the subcellular
compartment staining also deﬁnes that both NS5A and
FKBP38 localize in the mitochondria and ER. The result of
ER localization of FKBP38 is consistent with the very recent
reports [31,32]. More importantly, it was shown that, besides
ER, NS5A could also reside in the mitochondria. It should
be noted that most other viral proteins could localize in the
mitochondria and exert their functions. For example, the X
protein of hepatitis B virus (HBx) localizes in mitochondria
and leads to the alteration of transmembrane potential [33].
Moreover, other viral proteins such as vMIA protein of
cytomegalovirus, Kaposi’s sarcoma-associated herpesvirus
mitochondrial K7 protein, Vpr protein from human immuno-
deﬁciency virus-1, all localize in the mitochondria and exert
their pro- or anti-apoptotic functions [34]. Considering that
Bcl-2 expression is deﬁcient in liver tumor cells and suppres-
sion of FKBP38 in NS5A stable Huh7 hepatoma cells could
result in the increasing number of apoptotic cells while vector
cells could not, we speculate that NS5A may mimic the func-
tion of Bcl-2 and thus inhibit apoptosis.
In summary, we have found a novel interaction between
NS5A and FKBP38 and their mitochondrial and ER localiza-
tion. More importantly, such interaction implies a new mech-
anism for NS5A to evade apoptosis. However, the exact
mechanism downstream the interaction need to be further
elucidated.
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